News and press releases

PPTA member companies are committed to providing safe and effective therapies and PPTA understands that patients who rely on these often life-saving therapies may have concerns about the possible transmission of Swine Influenza Virus through them in view of the recent outbreak in humans. Therapies produced by PPTA members remain safe and available.

PPTA members are committed to providing safe and effective therapies and PPTA understands that patients who rely on plasma protein therapies may have concerns about the possible transmission of highly virulent strains of influenza H5N1 viruses through these therapies. Therefore, PPTA members continue to work to ensure that these viruses or any other emerging disease, do not compromise the safety of plasma protein therapies.

The Plasma Protein Therapeutics Association (PPTA) appreciates actions taken by the FDA and the Blood Products Advisory Committee (BPAC) with respect to the safety of albumin.

The Plasma Protein Therapeutics Association (PPTA) is the international trade association and standards-setting organization for the world's major producers of plasma-derived and recombinant analog therapies.